Where we come from
Although firmly rooted in Germany, today we are very much a growing global business. As an integrated research and development company, we have a strong track record of bringing effective pain treatments and state-of-the-art technologies to patients. Our high level of investment in R&D is testament to our unwavering commitment to innovation.
Grünenthal celebrates its 75th anniversary. It is also the 60th year since the market withdrawal of Thalidomide.
With the European rights (except Spain and the U.K.) for the lipid-lowering agent Crestor™, as well as the Swiss company Mestex AG, with its innovative investigational medicine RTX (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee, we complete two further significant acquisitions.